Collegium Pharmaceutical, Inc. (COLL) is a leading specialty pharmaceutical company, incorporated in 2003 and headquartered in Stoughton, Massachusetts, USA. The company is committed to developing and commercializing innovative pharmaceutical products to promote the management and treatment of an array of medical conditions.
The primary focus of Collegium Pharmaceutical, Inc. is on developing advanced, differentiated products for the treatment of pain. The company is known for its unique and proprietary DETERx technology platform, which is designed to provide extended-release delivery, enabling patients with difficulty swallowing to still be able to take their medication by sprinkling it onto food.
Collegium Pharmaceutical, Inc. flagship product is Xtampza ER (oxycodone), an abuse-deterrent, extended-release oral formulation of oxycodone approved by FDA. The drug aims at managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Its uniqueness lies in the patent-protected DETERx technology that maintains the extended-release and steady analgesic effects and its ability to resist methods of manipulation commonly associated with opioid abuse, such as chewing, crushing or dissolving.
In addition to Xtampza ER, other products in Collegium's portfolio include Nucynta ER (tapentadol extended-release tablets), a strong analgesic for controlling chronic pain in adults, and Nucynta (tapentadol), an immediate-release variant for controlling acute pain in adults.
Collegium Pharmaceutical, Inc. has remained committed to its mission to deliver top-notch pharmacotherapy in areas of high unmet medical needs, with pain management being paramount. By investing in research and innovation, the company remains at the forefront of providing ideal and overall solutions for pain mitigation. It maintains a corporate culture that prioritizes ethical behavior and accountability, fostering core values of integrity, patient focus, trust and respect, teamwork, and the pursuit of excellence.
The company is listed on the NASDAQ and caters to the medical communities within the United States. By offering innovative solutions for pain management, it continues to uphold its dedication to significantly improving the lives of people with painful conditions, ensuring its position as a leader in the development of pain management pharmaceuticals.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Oppenheimer has initiated coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a $50 price target. This new rating is above the current average analyst rating of "buy" and mean price target of $48.86 for the company. The full details of this report require a premium subscription.
The article provides an AI-generated quantitative analysis for Collegium Pharmaceutical Inc. (NASDAQ: COLL), indicating weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, identifying support and resistance levels. The report highlights elevated downside risk due to the absence of long-term support signals.
Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.